Méndez-Valdés, G.; Gómez-Hevia, F.; Lillo-Moya, J.; González-Fernández, T.; Abelli, J.; Cereceda-Cornejo, A.; Bragato, M.C.; Saso, L.; Rodrigo, R.
Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. Biomedicines 2023, 11, 718.
https://doi.org/10.3390/biomedicines11030718
AMA Style
Méndez-Valdés G, Gómez-Hevia F, Lillo-Moya J, González-Fernández T, Abelli J, Cereceda-Cornejo A, Bragato MC, Saso L, Rodrigo R.
Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. Biomedicines. 2023; 11(3):718.
https://doi.org/10.3390/biomedicines11030718
Chicago/Turabian Style
Méndez-Valdés, Gabriel, Francisca Gómez-Hevia, José Lillo-Moya, Tommy González-Fernández, Joaquin Abelli, Antonia Cereceda-Cornejo, Maria Chiara Bragato, Luciano Saso, and Ramón Rodrigo.
2023. "Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies" Biomedicines 11, no. 3: 718.
https://doi.org/10.3390/biomedicines11030718
APA Style
Méndez-Valdés, G., Gómez-Hevia, F., Lillo-Moya, J., González-Fernández, T., Abelli, J., Cereceda-Cornejo, A., Bragato, M. C., Saso, L., & Rodrigo, R.
(2023). Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. Biomedicines, 11(3), 718.
https://doi.org/10.3390/biomedicines11030718